© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
GI Cancers
Significant Disease Control Achieved With Nivolumab/Temozolomide Combo in Neuroendocrine Tumors
May 27, 2020
“Although these are early data, we are encouraged by these findings. The depth of response is particularly impressive in some patients."
Immunotherapy-Based Combos May be Necessary in Neuroendocrine Neoplasms
May 22, 2020
The immune checkpoint inhibitor induced 1 objective response but appeared safe as treatment of patients with metastatic high-grade neuroendocrine neoplasms in 2 open-label phase 2 clinical trials.
Trastuzumab Deruxtecan Receives Orphan Drug Designation from FDA for Gastric Cancer
May 22, 2020
Fam-trastuzumab deruxtecan-nxki has received an Orphan Drug designation for the treatment of patients with gastric or gastroesophageal junction cancer.
Pembrolizumab Shows Durable Response in Advanced Unresectable Anal Cancer
May 19, 2020
Van K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.
FDA Denies Approval of Avapritinib in Fourth-Line GIST
May 15, 2020
The New Drug Application for avapritinib as treatment of unresectable or metastatic fourth-line gastrointestinal stromal tumor was refused by the FDA, according to a recently issued complete response letter.
Liquid Biopsies Become More Common for Gastric and GI Cancers
May 13, 2020
Joseph Kim, MD, discusses the utility of liquid biopsies in patients with gastric or gastrointestinal cancer at the 2020 GI Cancers Symposium held by the American Society of Clinical Oncology.
FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan in HER2+ Gastric Cancer
May 11, 2020
Trastuzumab deruxtecan received Breakthrough Therapy Designation for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.
Concepts for Targeting the Metastatic Process in Pancreatic Cancer
May 03, 2020
In an interview with Targeted Oncology, Gregory L. Beatty, MD, PhD, discussed the science behind the development of metastases in pancreatic tumors, including how metastases differ in various sites in the body. He also reviewed the treatment options for this disease.
Treating Early Onset Colorectal Cancer in Young Adults
April 29, 2020
In an interview with Targeted Oncology following SOGO 2020, Andrea Cercek, MD, discussed the rising incidence of CRC in young adults in detail. She also advised community oncologists who encounter these patients in their clinics.
Updated Analysis Confirms Safety of Eryaspase in Advanced Metastatic Pancreatic Cancer
April 22, 2020
"The third independent safety review has once again confirmed the favorable safety profile of our lead product candidate eryaspase, and the trial has now surpassed 75% of the planned target enrollment."